BioLineRx Ltd.

BLRX Nasdaq SEC CIK 1498403
Follow BioLineRx Ltd. Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 USD · IFRS
EPS, diluted -
Revenue by quarter
$5.4M
$304K
Q2 24 Q2 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income12 fiscal years
  • Revenue
  • Net income
−$75M−$50M−$25M$0$25M$50MFY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$1.2M−$2M
FY24$28.9M−$9.2M
FY23$4.8M−$60.6M
FY22$0−$25M
FY21$0−$27.1M
FY20-−$30M
FY19-−$25.4M
FY18-−$23M
FY17-−$24.4M
FY16-−$15.8M
FY15-−$14.4M
FY14--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−1500%−1000%−500%0%500%FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2580.5%−871.8%−171.7%
FY2468%−70.5%−31.9%
FY2323.1%−1035.3%−1262.8%
FY22---
FY21---
FY20---
FY19---
FY18---
FY17---
FY16---
FY15---
FY14---
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$8.1M
FY24−$43.9M
FY23−$22.7M
FY22−$26.4M
FY21−$23.7M
FY20−$23.2M
FY19−$22.7M
FY18−$24.4M
FY17−$20.9M
FY16−$14.6M
FY15−$16.9M
FY14-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • BioLineRx Ltd.
  • Healthcare median
−1500%−1000%−500%0%FY15FY17FY19FY21FY23FY25
Show the numbers
YearBioLineRx Ltd.Healthcare median
FY25−171.7%−30.6%
FY24−31.9%−47%
FY23−1262.8%−58%
FY22-−80.4%
FY21-−71.9%
FY20-−62.2%
FY19-−46.3%
FY18-−49.6%
FY17-−45.9%
FY16-−36%
FY15-−38.4%
FY14-−35.5%